Vir Biotechnology, Inc.VIREarnings & Financial Report
Nasdaq
VIR Q3 2025 Key Financial Metrics
Revenue
$240.0K
Gross Profit
N/A
Operating Profit
$-173.4M
Net Profit
$-163.1M
Gross Margin
N/A
Operating Margin
-72267.9%
Net Margin
-67975.4%
YoY Growth
-89.9%
EPS
$-1.17
Financial Flow
Vir Biotechnology, Inc. Q3 2025 Financial Summary
Vir Biotechnology, Inc. reported revenue of $240.0K for Q3 2025, with a net profit of $-163.1M (-67975.4% margin). Cost of goods sold was N/A, operating expenses totaled N/A.
Key Financial Metrics
| Total Revenue | $240.0K |
|---|---|
| Net Profit | $-163.1M |
| Gross Margin | N/A |
| Operating Margin | -72267.9% |
| Report Period | Q3 2025 |
Vir Biotechnology, Inc. Annual Revenue by Year
Vir Biotechnology, Inc. annual revenue history includes year-by-year totals (for example, 2024 revenue was $74.2M).
| Year | Annual Revenue |
|---|---|
| 2024 | $74.2M |
| 2023 | $86.2M |
| 2022 | $1.6B |
Income Statement
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $16.8M | $56.4M | $3.1M | $2.4M | $12.4M | $3.0M | $1.2M | $240000 |
| YoY Growth | -66.0% | -10.5% | -19.0% | -9.8% | -26.3% | -94.6% | -60.5% | -89.9% |
Balance Sheet
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $1.92B | $1.79B | $1.67B | $1.50B | $1.40B | $1.31B | $1.19B | $1.02B |
| Liabilities | $328.8M | $246.6M | $235.9M | $257.6M | $248.4M | $263.9M | $245.1M | $223.4M |
| Equity | $1.59B | $1.55B | $1.43B | $1.24B | $1.15B | $1.04B | $947.5M | $796.1M |
Cash Flow
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-107.9M | $-109.4M | $-77.8M | $-171.5M | $-87.6M | $-78.1M | $-120.2M | $-167.6M |